Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Shares Outstanding

Last Annual Value

47.66M

3-Year CAGR

15%

5-Year CAGR

21%

10-Year CAGR

10%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of shares-outstanding

SERA · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
47.66M
15.2%9.1%N/A 
44.68M
1.3%1.5%N/A
42.16M
6.8%4.2%4.4%
95.19M
81.3%101.9%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
99.07M
-2.1%0.9%N/A
73.74M
1.5%1.6%14.2%
30.48M
58.5%47.0%36.8%
30.71M
64.0%60.6%86.9%
36.24M
0.2%8.5%86.7%
101.95M
34.7%23.1%N/A
47.93M
299.3%343.8%205.0%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245